Clinical Report: Diagnostic Significance of First-Morning Urine HPV Testing
Overview
This study evaluates the diagnostic performance of first-morning urine (FMU) HPV testing for detecting high-grade cervical lesions (CIN2+) compared to traditional cervical testing.
Background
Cervical cancer is a significant health concern, particularly in low- and middle-income countries, where screening participation is often low due to various barriers. High-grade cervical lesions are precursors to invasive cancer, making effective screening essential. Urine-based HPV testing, particularly FMU, presents a non-invasive alternative.
Data Highlights
Group
FMU Detection Rate
Cervical Cancer
96.25%
High-Grade Lesion/CIN2–3
86.67%
Low-Grade Lesion/CIN1
58.00%
No Lesion
28.00%
Key Findings
FMU HPV testing achieved a sensitivity of 90.50% and specificity of 67.00% for detecting CIN2+ lesions.
Traditional cervical testing had a sensitivity of 93.00% and specificity of 64.67% for the same lesions.
FMU testing showed higher per-protocol compliance (97.20% vs 84.80%) compared to traditional testing.
Patient satisfaction was higher for FMU testing (95.40% vs 79.60%).
No significant differences in diagnostic performance were found between FMU and traditional testing (P>0.05).
Clinical Implications
The findings suggest that FMU HPV testing could serve as a viable alternative to traditional cervical testing, particularly in settings where patient compliance is a challenge. Its non-invasive nature may encourage more women to participate in screening programs.
Conclusion
FMU HPV testing demonstrates comparable diagnostic performance to traditional methods.
